RBC Capital keeps Outperform on CAE and lifts price target to $53
RBC Capital raised its price target on CAE shares from $47 to $53 and kept its Outperform rating. TradingView reports the data, citing Benzinga reference data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
RBC Capital kept its Outperform rating on CAE shares and raised its price target from $47 to $53, an increase of 12.8%. According to figures reported by TradingView, the new target implies upside of 31.9% from the November 12 close of $40.19.
The report notes that the price target and rating data come from Benzinga. It also stresses that the information is not a personal recommendation and does not constitute investment advice.
why it matters
Price target revisions reflect an analyst's view on a single company and usually do not shift the broader market. For investors, the update is one reference point when studying the stock, but decisions should rest on their own goals and on wider information about the company.
tags
instruments
on polymarket
sources
- RBC Capital maintains CAE at Outperform, raises price target to $53 from $47 — TradingView, 13 November 2026 at 15:17 UTC
- RBC Capital maintains Liftoff Mobile at Outperform, raises price target to $38 from $35 — TradingView, 13 November 2026 at 15:23 UTC
- RBC Capital maintains Visteon at Outperform, raises price target to $102 from $100 — TradingView, 13 November 2026 at 15:31 UTC
- RBC Capital maintains Apotex Health at Outperform, raises price target to $46 from $43 — TradingView, 13 November 2026 at 15:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗